Dr. Oz’s online health site seeks addiction expert, Dr. Cidambi’s views on Probuphine, which was recently approved by the FDA. Probuphine is intended for treatment for opioid dependence and it is used to treat individuals suffering from opiate withdrawal and opiate cravings. Dr. Cidambi, Center for Network Therapy’s medical director argues why Probuphine will flop.
Dr. Cidambi is a leader in addiction treatment and innovator of safe and effective ambulatory (outpatient) detoxification level of care for alcohol, benzodiazepines, opiates, and suboxone. Prior to founding the Center for Network Therapy, she completed her residency in Psychiatry at Maimonides Medical Center in Brooklyn and an Addiction Medicine Fellowship at NYU/Bellevue Hospital in New York. Due to the successful detoxification program, Dr. Cidambi was featured frequently by media outlets, including NPR, CBS, NY Times, and Wall Street Journal.